Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02039947
Recruitment Status : Completed
First Posted : January 20, 2014
Last Update Posted : April 3, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 12, 2017
  Actual Study Completion Date : February 14, 2018
  Certification/Extension First Submitted : March 30, 2018